 FibroGen, Inc. NASDAQ:FGEN has a key catalyst Thursday when FDAs Cardiovascular and Renal Drugs Advisory Committee will issue its recommendation on the companys new drug application for roxadustat. The committee is scheduled to meet between 9:30 a.m. 